Bioventix PLC (AIM:BVXP)

Market Cap	95.61M
Revenue (ttm)	13.12M
Net Income (ttm)	7.58M
Shares Out	5.22M
EPS (ttm)	1.43
PE Ratio	12.77
Forward PE	13.45
Dividend	1.50 (8.20%)
Ex-Dividend Date	Nov 6, 2025

Volume	5,361
Average Volume	22,737
Open	1,850.00
Previous Close	1,900.00
Day's Range	1,800.00 - 1,900.00
52-Week Range	1,750.00 - 3,795.00
Beta	0.63
RSI	31.57
Earnings Date	Dec 29, 2025

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 12
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.